Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
GE Healthcare Imanet is an imaging solutions business, who's core focus has been conducting exploratory phase positron emission tomography (PET) imaging studies to aid in drug development for the pharma industry since 2001.
How can early and effective decision making be made easier with novel imaging of biomarkers and high quality quantitative imaging trials? Pharma and medical device companies have been answering this question with the support of GE Healthcare’s Imanet – an imaging solutions business – for the last ten years.
From PET microdosing to dose-occupancy profiles, PET imaging assists decision makers to select the best drug candidate, monitor treatment response, and make informed portfolio management decisions.
To be really successful, we also believe that imaging in support of pharma and device trials needs to address a number of very specific issues around quality, choice of imaging sites, novel imaging methods, and analysis methods. At Imanet we combine PET imaging with our second area of emphasis – broad clinical R&D imaging capabilities to provide a full imaging solutions service from imaging protocol development to analysis of the image data using dedicated methodology and software tools. Our in-house team, tasked with delivering all the services normally expected of an imaging contract research organization (CRO), including blinded read hosting, operates out of centers of expertise in the US, UK, Norway, Finland, Sweden, and India.
Imanet’s PET imaging services for drug development have emerged as both tactical and strategic methods to evaluate drug candidates in specific trials and drug programs. Radiotracers for PET have been used extensively for product selection and dosage selection in microdosing to Phase II studies. The in vivo monitoring of treatment response at a molecular level using PET is also well suited for molecularly targeted therapeutic drugs in development. De novo tracer development or radiolabeling of therapeutic candidates allow for subsequent down-selection of molecules in a drug portfolio via in vitro, ex vivo, and in vivo preclinical methods.
The success of our clients’ use of PET imaging solutions is critically dependent on the most effective study design that meets the endpoints in a timely and economic manor. As an imaging solutions business, Imanet provides a comprehensive imaging trial management service encompassing the initial design through to reporting end points.
Imanet has insights into the challenges of PET in drug trials and experience providing solutions using PET imaging in clinical trials worldwide. To contact Imanet about the research services we provide, please e-mail imanet@ge.com.
General inquiries: imanet@ge.com
www.imanet.com
| UK: Hammersmith Imanet Tel. +44 (0) 20 8383 3162 hammersmithimanet@ge.com |
Finland: Turku Imanet Tel. +358 (0) 2 4782 662 turkuimanet@ge.com |
Sweden: Uppsala Imanet Tel: +46 (0)18 66 68 00 uppsala.imanet@ge.com |